| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
1,518,000 |
| Market
Cap: |
10.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.2 - $18.63 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kala Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for diseases of the eye. Co.'s two marketed products are EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Co. is also progressing its pipeline of proprietary programs targeted to address front and back of the eye diseases, including KPI-287 and glucocorticoid receptor modulators.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
11,400 |
11,400 |
3,865,837 |
| Total Sell Value |
$0 |
$76,777 |
$76,777 |
$1,938,481 |
| Total People Sold |
0 |
6 |
6 |
7 |
| Total Sell Transactions |
0 |
6 |
6 |
15 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2022-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(9) |
15,430 |
|
- |
|
| Brazzell Kim |
SEE REMARKS |
• – – |
2022-01-04 |
4 |
AS |
$1.30 |
$4,555 |
D/D |
(3,504) |
288,345 |
|
-46% |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-01-04 |
4 |
AS |
$1.30 |
$12,373 |
D/D |
(9,518) |
259,158 |
|
-46% |
|
| Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2022-01-04 |
4 |
AS |
$1.30 |
$3,705 |
D/D |
(2,850) |
133,208 |
|
-46% |
|
| Trachtenberg Eric |
SEE REMARKS |
• – – |
2022-01-04 |
4 |
AS |
$1.30 |
$3,705 |
D/D |
(2,850) |
113,816 |
|
-46% |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2022-01-04 |
4 |
AS |
$1.30 |
$4,490 |
D/D |
(3,454) |
118,591 |
|
-46% |
|
| Blumenkranz Mark S. |
|
– • – |
2021-11-15 |
4 |
A |
$0.00 |
$0 |
I/I |
5,183,355 |
38,965 |
|
- |
|
| Blumenkranz Mark S. |
|
– • – |
2021-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
157,765 |
157,765 |
|
- |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2021-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
295,657 |
295,657 |
|
- |
|
| Chen Hongming |
CHIEF SCIENTIFIC OFFICER |
• – – |
2021-10-27 |
4 |
AS |
$1.82 |
$38,313 |
D/D |
(21,051) |
204,515 |
|
-27% |
|
| Trachtenberg Eric |
SEE REMARKS |
• – – |
2021-10-26 |
4 |
AS |
$1.80 |
$17,008 |
D/D |
(9,449) |
116,666 |
|
-37% |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2021-10-26 |
4 |
AS |
$1.80 |
$49,676 |
D/D |
(27,598) |
268,676 |
|
-37% |
|
| Chen Hongming |
CHIEF SCIENTIFIC OFFICER |
• – – |
2021-10-26 |
4 |
AS |
$1.80 |
$17,008 |
D/D |
(9,449) |
225,566 |
|
-37% |
|
| Bazemore Todd |
CHIEF OPERATING OFFICER |
• – – |
2021-10-26 |
4 |
AS |
$1.80 |
$22,579 |
D/D |
(12,544) |
122,045 |
|
-37% |
|
| Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2021-10-26 |
4 |
AS |
$1.80 |
$17,008 |
D/D |
(9,449) |
136,058 |
|
-37% |
|
| Brazzell Kim |
CHIEF MEDICAL OFFICER |
• – – |
2021-10-26 |
4 |
AS |
$1.80 |
$22,963 |
D/D |
(12,757) |
291,849 |
|
-37% |
|
| Chen Hongming |
CHIEF SCIENTIFIC OFFICER |
• – – |
2021-06-29 |
4 |
AS |
$5.56 |
$30,847 |
D/D |
(5,548) |
235,015 |
|
-61% |
|
| Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2021-06-28 |
4 |
AS |
$5.77 |
$14,148 |
D/D |
(2,452) |
145,507 |
|
-62% |
|
| Brazzell Kim |
CHIEF MEDICAL OFFICER |
• – – |
2021-06-28 |
4 |
AS |
$5.77 |
$17,506 |
D/D |
(3,034) |
300,962 |
|
-62% |
|
| Bazemore Todd |
CHIEF OPERATING OFFICER |
• – – |
2021-06-28 |
4 |
AS |
$5.77 |
$16,796 |
D/D |
(2,911) |
0 |
|
-62% |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2021-06-28 |
4 |
AS |
$5.77 |
$43,771 |
D/D |
(7,586) |
296,274 |
|
-62% |
|
| Chen Hongming |
CHIEF SCIENTIFIC OFFICER |
• – – |
2021-06-28 |
4 |
AS |
$5.77 |
$14,148 |
D/D |
(2,452) |
240,563 |
|
-62% |
|
| Trachtenberg Eric |
SEE REMARKS |
• – – |
2021-06-28 |
4 |
AS |
$5.77 |
$14,148 |
D/D |
(2,452) |
126,115 |
|
-62% |
|
| Paull Robert Bradley |
|
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
40,000 |
|
- |
|
| Shah Rajeev M. |
|
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
144 Records found
|
|
Page 3 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.19 (2.79%) 
